Test ID: FBLP
B-Cell Lymphoma, FISH, Blood or Bone Marrow
Secondary ID
A test code used for billing and in test definitions created prior to November 2011
NY State Approved
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For
Suggests clinical disorders or settings where the test may be helpful
Detecting an abnormal clone associated with the common chromosome anomalies seen in patients with B-cell lymphoma, specifically Burkitt, mantle cell, follicular, diffuse large B-cell, and MALT lymphoma
Individual probes can also be utilized to identify specific chromosome anomalies in patients with B-cell lymphoma and track the response to therapy.
Reflex Tests
Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ADD1F | One Additional FISH Probe | No | No |
| ADD2F | Two Additional FISH Probes | No | No |
| ADD4F | Four Additional FISH Probes | No | No |
| ADD3F | Three Additional FISH Probes | No | No |
| ADD5F | Five Additional FISH Probes | No | No |
| ADD6F | Six Additional FISH Probes | No | No |
| ADD7F | Seven Additional FISH Probes | No | No |
| ADD8F | Eight Additional FISH Probes | No | No |
| ADD9F | Nine Additional FISH Probes | No | No |
| ADD10 | Ten Additional FISH Probes | No | No |
| ADD11 | Eleven Additional FISH Probes | No | No |
| ADD12 | Twelve Additional FISH Probes | No | No |
| 14FP | Fourteen Additional FISH Probes | No | No |
| 13FP | Thirteen Additional FISH Probes | No | No |
| 15FP | Fifteen Additional FISH Probes | No | No |
| 16FP | Sixteen Additional FISH Probes | No | No |
| 17FP | Seventeen Additional FISH Probes | No | No |
| 18FP | Eighteen Additional FISH Probes | No | No |
| 19FP | Nineteen Additional FISH Probes | No | No |
| 20FP | Twenty Additional FISH Probes | No | No |
| 21FP | Twenty One Additional FISH Probes | No | No |
| 22FP | Twenty Two Additional FISH Probes | No | No |
| 23FP | Twenty Three Additional FISH Probes | No | No |
| 24FP | Twenty Four Additional FISH Probes | No | No |
| 25FP | Twenty Five Additional FISH Probes | No | No |
| 26FP | Twenty Six Additional FISH Probes | No | No |
| 27FP | Twenty Seven Additional FISH Probes | No | No |
| 28FP | Twenty Eight Additional FISH Probes | No | No |
| 29FP | Twenty Nine Additional FISH Probes | No | No |
| 30FP | Thirty Additional FISH Probes | No | No |
Testing Algorithm
Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
Indicate which subtype of B-cell lymphoma is suspected as well as which anomalies need to be investigated from the following profile.
t(8;14), MYC/IGH
t(8q24.1;var), MYC
t(11;14), CCND1/IGH
t(11;18), BIRC3/MALT1
t(14;18), IGH/MALT1
t(14;18), IGH/BCL2
t(3q27;var), BCL6
t(8;22), MYC/IGL
If the patient is being tracked for known anomalies, indicate which anomalies need to be investigated.
The number of probes ordered will determine the price of the testing. When this test is ordered, a charge for 2 FISH probes and interpretation is included. If additional probes or the entire panel are ordered, additional probes charges will be added.
See Malignant Lymphoma, Guideline for Bone Marrow Staging Studies in Special Instructions
Special Instructions and Forms
Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name
A short description of the method used to perform the test
Fluorescence In Situ Hybridization (FISH)
Reporting Name
A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases
Lists additional common names for a test, as an aid in searching
8;22 translocation
API2/MALT1
B Cell
BCL2/IGH
BCL6
BIRC3
BIRC3/MALT1
Burkitt Lymphoma
c-MYC/IGH
c-MYC/IGL
c-MYC/Lambda
CCND1/IGH
Cyclin D1
Diffuse Large Cell Lymphoma
ENMZL
FMCL
Follicular Lymphoma
IGH/MALT1
IGL
Lambda
MALT Lymphoma
MALT1
Mantle Cell Lymphoma (MCL) (FISH)
Marginal Zone Lymphoma
MCL (Mantle Cell Lymphoma) FISH
MYC
MYC/IGH
MYC/IGL
MYC/Lambda
t(11;14)
t(11;18)
t(14;18)
t(2;8)
t(8;14)
t(8;22)
Translocation 11;14
Translocation 11;18
Translocation 14;18
Translocation 2;8
Translocation 8;14
Translocation 8;22
Specimen Type
Describes the specimen type needed for testing
Specimen Required
Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Provide a reason for referral with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.
Forms:
1. Cytogenetics Hematologic FISH Panel Patient Information Sheet (Supply T603) in Special Instructions
2. If not ordering electronically, submit a Cytogenetics Hematologic Disorders Request Form (Supply T607) with the specimen.
Advise Express Mail or equivalent if not on courier service.
Submit only 1 of the following specimens:
Preferred:
Specimen Type: Blood
Container/Tube: Green top (sodium heparin)
Specimen Volume: 7-10 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Other anticoagulants are not recommended and are harmful to the viability of the cells.
Specimen Type: Bone marrow
Container/Tube: Green top (sodium heparin)
Specimen Volume: 1-2 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Other anticoagulants are not recommended and are harmful to the viability of the cells.
Acceptable:
Specimen Type: Touch prep or fresh tissue
Specimen Minimum Volume
Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | NA |
| Lipemia | NA |
| Icterus | NA |
| Other | Clotted blood or bone marrow |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Varies | Ambient (preferred) | |
| Refrigerated | ||
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Lymphoid neoplasms are known to be complex and the prognosis and clinical course of patients with lymphoma is highly variable. Genetic abnormalities have emerged as 1 of the most reliable criteria for categorizing lymphomas. Several chromosome anomalies and variants of these anomalies have been associated with various kinds of lymphoma (see Table).
| Common chromosome anomalies in lymphomas | ||
| Lymphoma Type | Chromosome Anomaly | FISH Probe |
| Burkitt | t(8;14)(q24;q32) | MYC/IGH |
| t(8;22)(q24;q11.2) | MYC/IGL | |
| t(22;var)(q11.2;var) | IGL | |
| Mantle cell | t(11;14)(q13;q32) | CCND1-XT/IGH |
| Follicular | t(14;18)(q32;q21) | IGH/BCL2 |
| Diffuse large B-cell | t(3;var)(q27;var) | BCL6 |
| t(14;18)(q32;q21) | IGH/BCL2 | |
| t(8;14)(q24;q32) | MYC/IGH | |
| t(8;22)(q24;q11.2) | MYC/IGL | |
| t(22;var)(q11.2;var) | IGL | |
| Marginal zone of MALT type | t(11;18)(q21;q21) | BIRC3/MALT1 |
| t(14;18)(q32;q21) | IGH/MALT1 | |
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
An interpretive report will be provided.
Interpretation
Provides information to assist in interpretation of the test results
A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal reference range for any given probe.
The absence of an abnormal clone does not rule the presence of neoplastic disorder.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This test is not approved by the FDA and it is best used as an adjunct to existing clinical and pathologic information.
Clinical Reference
Provides recommendations for further in-depth reading of a clinical nature
1. Remstein ED, Kurtin PJ, Buno I, et al: Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 2000 Sep;110(4):856-862
2. Remstein ED, Kurtin PJ, James CD, et al: Mucosa-associated lymphoid tissue lymphomas with t(11;18) (q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol 2002 Jul;161(1):63-71
3. Remstein ED, Dogan A, Einerson RR, et al: The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006 Dec;30(12):1546-1553H636
Method Description
Describes how the test is performed and provides a method-specific reference
Anomalies involving BCL6, c-MYC, and IGL are detected using a break-apart FISH probe. If a MYC abnormality is detected, reflex testing will be performed to identify the translocation partner. Translocations involving fusion of CCND1 and IGH; BCL2 and IGH; MYC and IGH; BIRC3 and MALT1; IGH and MALT1; and MYC and IGL are detected using dual-color, dual-fusion (D-FISH) strategies. A total of 200 nuclei are scored for the break-apart probe set. For each D-FISH probe set, 500 interphase nuclei are scored and results for each abnormal probe(s) are expressed as percent abnormal nuclei.(Brockman SR, Paternoster SF, Ketterling RP, et al: New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet 2003;145:144-51)
Day(s) and Time(s) Test Performed
Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday; 6 a.m.-9 p.m., Saturday, Sunday; 6 a.m.-4 p.m.
Analytic Time
Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time
Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
The location of the laboratory that performs the test
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
B-Cell Lymphoma, FISH, Blood or Bone Marrow
88271 x 2-DNA probe, each
88275 x 2-Interphase in situ hybridization
88291-Interpretation and report
One Additional FISH Probe
88271-DNA probe, each (if appropriate)
88275-Interphase in situ hybridization (if appropriate)
Two Additional FISH Probes
88271 x 2-DNA probe, each (if appropriate)
88275-Interphase in situ hybridization (if appropriate)
Three Additional FISH Probes
88271 x 3-DNA probe, each (if appropriate)
88275-Interphase in situ hybridization (if appropriate)
Four Additional FISH Probes
88271 x 4-DNA probe, each (if appropriate)
88275 x 2-Interphase in situ hybridization (if appropriate)
Five Additional FISH Probes
88271 x 5-DNA probe, each (if appropriate)
88275 x 2-Interphase in situ hybridization (if appropriate)
Six Additional FISH Probes
88271 x 6-DNA probe, each (if appropriate)
88275 x 3-Interphase in situ hybridization (if appropriate)
Seven Additional FISH Probes
88271 x 7-DNA probe, each (if appropriate)
88275 x 3-Interphase in situ hybridization (if appropriate)
Eight Additional FISH Probes
88271 x 8-DNA probe, each (if appropriate)
88275 x 4-Interphase in situ hybridization (if appropriate)
Nine Additional FISH Probes
88271 x 9-DNA probe, each (if appropriate)
88275 x 4-Interphase in situ hybridization (if appropriate)
Ten Additional FISH Probes
88271 x 10-DNA probe, each (if appropriate)
88275 x 5-Interphase in situ hybridization (if appropriate)
Eleven Additional FISH Probes
88271 x 11-DNA probe, each (if appropriate)
88275 x 5-Interphase in situ hybridization (if appropriate)
Twelve Additional FISH Probes
88271 x 12-DNA probe, each (if appropriate)
88275 x 6-Interphase in situ hybridization (if appropriate)
Thirteen Additional FISH Probes
88271 x 13-DNA probe, each (if appropriate)
88275 x 6-Interphase in situ hybridization (if appropriate)
Fourteen Additional FISH Probes
88271 x 14-DNA probe, each (if appropriate)
88275 x 7-Interphase in situ hybridization (if appropriate)
Fifteen Additional FISH Probes
88271 x 15-DNA probe, each (if appropriate)
88275 x 7-Interphase in situ hybridization (if appropriate)
Sixteen Additional FISH Probes
88271 x 16-DNA probe, each (if appropriate)
88275 x 8-Interphase in situ hybridization (if appropriate)
Seventeen Additional FISH Probes
88271 x 17-DNA probe, each (if appropriate)
88275 x 8-Interphase in situ hybridization (if appropriate)
Eighteen Additional FISH Probes
88271 x 18-DNA probe, each (if appropriate)
88275 x 9-Interphase in situ hybridization (if appropriate)
Nineteen Additional FISH Probes
88271 x 19-DNA probe, each (if appropriate)
88275 x 9-Interphase in situ hybridization (if appropriate)
Twenty Additional FISH Probes
88271 x 20-DNA probe, each (if appropriate)
88275 x 10-Interphase in situ hybridization (if appropriate)
Twenty One Additional FISH Probes
88271 x21-DNA probe, each (if appropriate)
88275 x10-Interphase in situ hybridization (if appropriate)
Twenty Two Additional FISH Probes
88271 x22-DNA probe, each (if appropriate)
88275 x11-Interphase in situ hybridization (if appropriate)
Twenty Three Additional FISH Probes
88271 x23-DNA probe, each (if appropriate)
88275 x11-Interphase in situ hybridization (if appropriate)
Twenty Four Additional FISH Probes
88271 x24-DNA probe, each (if appropriate)
88275 x12-Interphase in situ hybridization (if appropriate)
Twenty Five Additional FISH Probes
88271 x25-DNA probe, each (if appropriate)
88275 x12-Interphase in situ hybridization (if appropriate)
Twenty Six Additional FISH Probes
88271 x26-DNA probe, each (if appropriate)
88275 x13-Interphase in situ hybridization (if appropriate)
Twenty Seven Additional FISH Probes
88271 x27-DNA probe, each (if appropriate)
88275 x13-Interphase in situ hybridization (if appropriate)
Twenty Eight Additional FISH Probes
88271 x28-DNA probe, each (if appropriate)
88275 x14-Interphase in situ hybridization (if appropriate)
Twenty Nine Additional FISH Probes
88271 x29-DNA probe, each (if appropriate)
88275 x14-Interphase in situ hybridization (if appropriate)
Thirty Additional FISH Probes
88271 x30-DNA probe, each (if appropriate)
88275 x15-Interphase in situ hybridization (if appropriate)
LOINC® Code Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| 27185 | Specimen | 31208-2 |
| 27186 | Specimen ID | In Process |
| G_701 | Source | N/A |
| 27188 | Order Date | N/A |
| G_703 | Reason For Referral | 42349-1 |
| 27190 | Method | 49549-9 |
| 27191 | Result | In Process |
| 27192 | Interpretation | 69965-2 |
| 27193 | Amendment | In Process |
| 27194 | Consultant | In Process |
| 27195 | Released Date | N/A |


